Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesdopetam Phase 2b in PD-LID
NCT04435431Phase 2Completed
- Sponsor
- IRLAB
- Start
- Oct 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of mesdopetam in Parkinson's disease (PD) (4 arms), sponsored by IRLAB. Primary endpoint: Change in Average Daily Hours of ON-time Without Troublesome Dyskinesia at 12 weeks. Started Oct 2020; status: completed.
02
Drugs
mesdopetam
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04435431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04435431.